- Home
- JHI vs NVRO Comparison
JHI vs NVRO Comparison
Compare JHI & NVRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JHI
- NVRO
- Stock Information
- Founded
- JHI 1971
- NVRO 2006
- Country
- JHI United States
- NVRO United States
- Employees
- JHI N/A
- NVRO N/A
- Industry
- JHI Trusts Except Educational Religious and Charitable
- NVRO Medical/Dental Instruments
- Sector
- JHI Finance
- NVRO Health Care
- Exchange
- JHI Nasdaq
- NVRO Nasdaq
- Market Cap
- JHI 124.3M
- NVRO 139.0M
- IPO Year
- JHI N/A
- NVRO 2014
- Fundamental
- Price
- JHI $14.09
- NVRO $4.68
- Analyst Decision
- JHI
- NVRO Hold
- Analyst Count
- JHI 0
- NVRO 14
- Target Price
- JHI N/A
- NVRO $7.97
- AVG Volume (30 Days)
- JHI 29.5K
- NVRO 574.3K
- Earning Date
- JHI 01-01-0001
- NVRO 02-19-2025
- Dividend Yield
- JHI 6.80%
- NVRO N/A
- EPS Growth
- JHI N/A
- NVRO N/A
- EPS
- JHI 1.05
- NVRO N/A
- Revenue
- JHI N/A
- NVRO $419,146,000.00
- Revenue This Year
- JHI N/A
- NVRO N/A
- Revenue Next Year
- JHI N/A
- NVRO $0.50
- P/E Ratio
- JHI $12.47
- NVRO N/A
- Revenue Growth
- JHI N/A
- NVRO N/A
- 52 Week Low
- JHI $11.63
- NVRO $3.17
- 52 Week High
- JHI $13.40
- NVRO $19.47
- Technical
- Relative Strength Index (RSI)
- JHI 57.83
- NVRO 62.11
- Support Level
- JHI $13.84
- NVRO $3.17
- Resistance Level
- JHI $14.17
- NVRO $3.99
- Average True Range (ATR)
- JHI 0.11
- NVRO 0.31
- MACD
- JHI 0.04
- NVRO 0.14
- Stochastic Oscillator
- JHI 84.62
- NVRO 96.81
About JHI John Hancock Investors Trust
John Hancock Investors Trust is a United States-based diversified, closed-end management investment company. It seeks to generate income for distribution to its shareholders. The secondary objective of the company is capital appreciation. The portfolio composition of the fund comprises corporate bonds, U.S. government agencies, preferred securities, asset-backed securities, common stocks, short-term investments, and others.
About NVRO Nevro Corp.
Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.